Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02053012 · ClinicalTrials.gov registry record

Investigating Reaction Time Among Children Who Snore

A clinical trial of Snoring, sponsored by Vidya Raman.

Completed
Registry status
93
Enrollment target
1
Study location

NCT02053012: Completed study of Snoring, sponsored by Vidya Raman.

NCT02053012 is a study of Snoring that has completed, run by Vidya Raman. The registered enrollment target is 93 participants, above the 41-participant average among 7 other Snoring trials with a reported enrollment target (127% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02053012, a study of Snoring, has completed, sponsored by Vidya Raman.

COMPLETED
Registry status
93 participants
Enrollment target
1
Study location

Study Summary

The investigators feel that children who have OSA or sleep-disordered breathing may have a different reaction time than normal variants. Children who have OSA are known to have behavioral and sleep patterns that are different. It makes sense their reaction time may be different than normal as well. We plan to measure reaction times via a 10 minute psychomotor vigilance test device in children who snore who are coming in for a sleep study or for adenotonsillectomy.

Primary Outcome

We plan to measure reaction times via a 10 minute psychomotor vigilance test (PVT, Ambulatory Monitoring Inc., NY) device.

Conditions Studied

Interventions

  • DEVICE PVT-192

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2014-01
Est. Completion 2018-02-23
Vidya Raman

5 total trials

What the finished NCT02053012 record still lists

NCT02053012 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target, above the 41-participant average among 7 other Snoring trials with a reported enrollment target (127% higher).

The record links to 1 condition, with Snoring appearing as the primary indexed condition, and to 1 intervention - of which PVT-192 is the first listed.

NCT02053012 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT02053012 about?

NCT02053012 is a clinical study titled "Investigating Reaction Time Among Children Who Snore". The investigators feel that children who have OSA or sleep-disordered breathing may have a different reaction time than normal variants. Children who have OSA are known to have behavioral and sleep patterns that are different. It makes sense their reaction time may be different than normal as well. ...

What is the current status of trial NCT02053012?

This trial is currently completed. The enrollment target is 93 participants. The study started on 2014-01. Estimated completion is 2018-02-23.

What conditions does trial NCT02053012 study?

This clinical trial studies the following conditions: Snoring.

What interventions are being tested in trial NCT02053012?

The interventions under investigation include: PVT-192 (DEVICE).

Who is sponsoring clinical trial NCT02053012?

This trial is sponsored by Vidya Raman, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02053012 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Snoring

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02053012, the US trial registry maintained by the National Library of Medicine. NCT02053012 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.